{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:43:26Z","timestamp":1774554206797,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ejca.2017.01.026","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T19:19:04Z","timestamp":1487963944000},"page":"245-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-8237","authenticated-orcid":false,"given":"Giandomenico","family":"Roviello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford A.","family":"Hudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Petrioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.01.026_bib1","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.ejca.2008.07.042","article-title":"The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer. Where does it fit?","volume":"33","author":"Eskens","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.01.026_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1634\/theoncologist.2009-0145","article-title":"Targeting signal transduction pathways in metastatic breast cancer a comprehensive review","volume":"15","author":"Rosen","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2017.01.026_bib3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2000.18.7.1423","article-title":"Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment","volume":"18","author":"Linderholm","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.026_bib4","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.01.026_bib5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejca.2017.01.026_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1586\/14737140.7.4.433","article-title":"Bevacizumab in the management of solid tumors","volume":"7","author":"Pa\u00f1ares","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2017.01.026_bib7","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2017.01.026_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2017.01.026_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2017.01.026_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2017.01.026_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.ejca.2017.01.026_bib12","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.01.026_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2017.01.026_bib14","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-15-3117","article-title":"BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer","volume":"22","author":"Benson","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.ejca.2017.01.026_bib15","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2017.01.026_bib16","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2017.01.026_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2017.01.026_bib18","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2017.01.026_bib19","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2010.29.3423","article-title":"Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial","volume":"29","author":"Spigel","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2017.01.026_bib20","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2017.01.026_bib21","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1200\/JCO.2012.44.7912","article-title":"AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent\/metastatic breast cancer","volume":"31","author":"Gianni","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.01.026_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.ejca.2017.01.026_bib23","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1200\/JCO.2008.21.6630","article-title":"Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer","volume":"27","author":"Gray","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.01.026_bib24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.5732\/cjc.011.10188","article-title":"Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial","volume":"30","author":"Guan","year":"2011","journal-title":"Chin J Cancer"},{"issue":"13","key":"10.1016\/j.ejca.2017.01.026_bib25","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"Hegewisch-Becker","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.01.026_bib26","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2014.58.3781","article-title":"Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Hensley","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9780","key":"10.1016\/j.ejca.2017.01.026_bib27","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(11)60545-X","article-title":"Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial","volume":"377","author":"Herbst","year":"2011","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ejca.2017.01.026_bib28","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2017.01.026_bib29","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2017.01.026_bib30","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2017.01.026_bib31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1200\/JCO.2014.57.2388","article-title":"Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole\/fulvestrant and avastin (LEA) study","volume":"33","author":"Mart\u00edn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2017.01.026_bib32","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2017.01.026_bib33","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2017.01.026_bib34","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.ejca.2017.01.026_bib35","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.01.026_bib36","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.01.026_bib37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/annonc\/mdv130","article-title":"Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial","volume":"26","author":"Passardi","year":"2015","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.ejca.2017.01.026_bib38","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ejca.2017.01.026_bib39","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.01.026_bib40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/annonc\/mdv065","article-title":"Randomized phase II\u2013III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial","volume":"26","author":"Pujol","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2017.01.026_bib41","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2017.01.026_bib42","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.01.026_bib43","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.01.026_bib44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","article-title":"Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial","volume":"11","author":"Robert","year":"2011","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2017.01.026_bib45","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"28","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2017.01.026_bib46","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2017.01.026_bib47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10120-014-0351-5","article-title":"Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)","volume":"18","author":"Shen","year":"2015","journal-title":"Gastric Cancer"},{"issue":"9980","key":"10.1016\/j.ejca.2017.01.026_bib48","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"issue":"5-6","key":"10.1016\/j.ejca.2017.01.026_bib49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000320520","article-title":"Treatment of colorectal cancer with and without bevacizumab: a phase III study","volume":"78","author":"Stathopoulos","year":"2010","journal-title":"Oncology"},{"issue":"19","key":"10.1016\/j.ejca.2017.01.026_bib50","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study","volume":"28","author":"Tebbutt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.01.026_bib51","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ejca.2017.01.026_bib52","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2017.01.026_bib53","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.01.026_bib54","article-title":"EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma","volume":"34","author":"Wick","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2017.01.026_bib55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12032-014-0035-3","article-title":"Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer","volume":"31","author":"Xie","year":"2014","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.01.026_bib56","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12032-014-0292-1","article-title":"Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial","volume":"32","author":"Zhao","year":"2015","journal-title":"Med Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2017.01.026_bib57","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2017.01.026_bib58","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/JTO.0000000000000366","volume":"10","author":"Zinner","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2017.01.026_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.1013","article-title":"Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: results of a multicenter national observational study","volume":"34","author":"Delaloge","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2017.01.026_bib60","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"JCO"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917300874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T23:03:47Z","timestamp":1568847827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917300874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":60,"alternative-id":["S0959804917300874"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.026","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}